| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8546608 | TAKEDA PHARMS USA | Proteasome inhibitors and methods of using the same |
Aug, 2024
(3 months from now) | |
| US8530694 | TAKEDA PHARMS USA | Proteasome inhibitors |
Aug, 2027
(3 years from now) | |
| US8003819 | TAKEDA PHARMS USA | Proteasome inhibitors |
Aug, 2027
(3 years from now) | |
| US7687662 | TAKEDA PHARMS USA | Proteasome inhibitors |
Aug, 2027
(3 years from now) | |
| US8859504 | TAKEDA PHARMS USA | Boronate ester compounds and pharmaceutical compositions thereof |
Jun, 2029
(5 years from now) | |
| US7442830 | TAKEDA PHARMS USA | Proteasome inhibitors |
Nov, 2029
(5 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9233115 | TAKEDA PHARMS USA | Proteasome inhibitors and methods of using the same |
Aug, 2024
(3 months from now) | |
| US8871745 | TAKEDA PHARMS USA | Proteasome inhibitors |
Aug, 2027
(3 years from now) | |
| US9175017 | TAKEDA PHARMS USA | Boronate ester compounds and pharmaceutical compositions thereof |
Jun, 2029
(5 years from now) | |
Ninlaro is owned by Takeda Pharms Usa.
Ninlaro contains Ixazomib Citrate.
Ninlaro has a total of 9 drug patents out of which 0 drug patents have expired.
Ninlaro was authorised for market use on 20 November, 2015.
Ninlaro is available in capsule;oral dosage forms.
Ninlaro can be used as use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Drug patent challenges can be filed against Ninlaro from 21 November, 2019.
The generics of Ninlaro are possible to be released after 20 November, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 20, 2020 |
| Orphan Drug Exclusivity(ODE) | Nov 20, 2022 |
| Orphan Drug Exclusivity(ODE-103) | Nov 20, 2022 |
Drugs and Companies using IXAZOMIB CITRATE ingredient
NCE-1 date: 21 November, 2019
Market Authorisation Date: 20 November, 2015
Treatment: Use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy
Dosage: CAPSULE;ORAL
NINLARO family patents
